Inside the unconventional FDA panel that could reshape the peptide industry

An FDA advisory panel led by Robert F. Kennedy Jr. is reviewing seven banned therapeutic peptides, including BPC-157, TB-500, and epitalon, amid concerns over safety and efficacy. The two-day meeting (July 23-24) includes panelists with ties to peptide research, sales, or prescription, marking an unconventional approach to regulatory evaluation.